SNDX Syndax Pharmaceuticals
- 21.970
- -0.410-1.83%
Syndax Pharmaceuticals News
Citigroup Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $30
Citigroup analyst Yigal Nochomovitz maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $32 to $30.
Syndax Pharmaceuticals Price Target Raised to $40.00/Share From $39.00 by Stifel
Syndax Pharmaceuticals Price Target Raised to $40.00/Share From $39.00 by Stifel
Syndax Pharmaceuticals Is Maintained at Buy by Stifel
Syndax Pharmaceuticals Is Maintained at Buy by Stifel
Stifel: Maintaining the Syndax Pharmaceuticals (SNDX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $39.00 to $40.00.
Stifel: Maintaining the Syndax Pharmaceuticals (SNDX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $39.00 to $40.00.
Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference
Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Buy Rating for Syndax Pharmaceuticals Amid Strong Financials and Promising Drug Candidate
Analysts' Top Healthcare Picks: Elanco Animal Health (ELAN), Syndax Pharmaceuticals (SNDX)
Syndax Pharmaceuticals Q1 Net Loss Widens
Syndax Pharmaceuticals (SNDX) reported a Q1 net loss Wednesday of $0.85 per diluted share, wider than a loss of $0.59 a year earlier. Analysts polled by Capital IQ expected a loss of $0.97. The compan
Syndax Pharmaceuticals Q1 2024 GAAP EPS $(0.85) Beats $(0.99) Estimate
Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.85) per share which beat the analyst consensus estimate of $(0.99) by 14.14 percent. This is a 44.07 percent decrease over losses
Syndax Pharmaceuticals | 10-Q: Quarterly report
Syndax Pharmaceuticals 1Q Loss $72.4M >SNDX
Syndax Pharmaceuticals 1Q Loss $72.4M >SNDX
Syndax Pharmaceuticals 1Q Loss/Shr 85c >SNDX
Syndax Pharmaceuticals 1Q Loss/Shr 85c >SNDX
Analysts' Opinions Are Mixed on These Healthcare Stocks: Addus Homecare (ADUS), BioCryst (BCRX) and Syndax Pharmaceuticals (SNDX)
HC Wainwright & Co. : The Syndax Pharmaceuticals (SNDX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $41.00.
HC Wainwright & Co. : The Syndax Pharmaceuticals (SNDX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $41.00.
Buy Rating Reaffirmed for Syndax Pharmaceuticals on Strong Drug Pipeline and Strategic Partnerships
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
Syndax Pharmaceuticals (NASDAQ:SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will participate in a fireside chat at the at Stifel 2024 Virtual Targeted Oncology Forum on Wednesday, April 17, 2024, at 11:00 a.m. ET.
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX), Inozyme Pharma (INZY) and PTC Therapeutics (PTCT)
Analysts Are Bullish on Top Healthcare Stocks: Syndax Pharmaceuticals (SNDX), Legend Biotech (LEGN)
Buy Rating Affirmed for Syndax Pharmaceuticals Amidst Strong Clinical Results and Strategic Growth Prospects
Live On CNBC, StemPoint Capital CIO Michelle Ross Mentioned Syndax Pharmaceuticals, Shares Spiked Higher
Live On CNBC, StemPoint Capital CIO Michelle Ross Mentioned Syndax Pharmaceuticals, Shares Spiked Higher
Analysis
Price Target
No Data
